Loading
IARC estimates 7,031 new cancer cases and 4,351 cancer deaths in Togo in 2024; the commonest new cancers are breast, cervix uteri and prostate. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Togo's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 1,701 | 50.2 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 746 | 24.4 | Cervical cancer |
| Prostate | 548 | 25.7 | Prostate cancer |
| Liver and intrahepatic bile ducts | 499 | 8.3 | Hepatocellular carcinoma |
| Colorectum | 453 | 7.8 | Colorectal cancer |
| Stomach | 330 | 6.1 | Gastric & gastro-oesophageal junction cancer |
| Bladder | 211 | 3.9 | Bladder & urothelial cancer |
| Ovary | 209 | 6.7 | Ovarian cancer |
| Pancreas | 150 | 2.8 | Pancreatic ductal adenocarcinoma |
| Trachea, bronchus and lung | 150 | 3.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 806 | 24.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 452 | 15.1 | Cervical cancer |
| Liver and intrahepatic bile ducts | 450 | 7.6 | Hepatocellular carcinoma |
| Prostate | 333 | 15.9 | Prostate cancer |
| Stomach | 265 | 5.1 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 260 | 4.8 | Colorectal cancer |
| Pancreas | 149 | 2.8 | Pancreatic ductal adenocarcinoma |
| Ovary | 145 | 4.9 | Ovarian cancer |
| Trachea, bronchus and lung | 139 | 2.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Bladder | 112 | 2.2 | Bladder & urothelial cancer |
No trial record in OnCo lists a site in Togo. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Togo.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Togo is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Togo is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.